Recent Updates
Recently added Catalysts
STXS Positive Sentiment

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Key Takeaway: Stereotaxis, a leader in surgical robotics, will participate in the Piper Sandler 37th Annual Healthcare Conference. CEO David Fischel is set to engage in a fireside discussion and hold one-on-one meetings on December 3rd, 2025. The company is currently experiencing significant regulatory progress and early commercial success.
Price reaction · baseline $2.32 (2025-11-21 close) · hit pre-market · clean, no other STXS news in the window
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Stereotaxis is achieving key regulatory milestones.
  • The company is demonstrating early commercial growth.
  • Participation in the Piper Sandler conference indicates investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~8 mo
Medium dilution risk
Lead asset
Vdrive Lasso navigation, Manual Lasso navigation
Phase 3 · Atrial Fibrillation

Full Press Release Details

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) --Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in thePiper Sandler 37th Annual Healthcare Conference.
David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings.
“This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the Piper Sandler conference."
About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visitwww.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statementswithin the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:David L. FischelChairman and Chief Executive Officer

Frequently Asked Questions

When will Stereotaxis participate in the conference?

Stereotaxis will participate in the conference on December 3rd, 2025.

Who is the CEO of Stereotaxis?

David Fischel is the Chairman and CEO of Stereotaxis.

What is the focus of Stereotaxis?

Stereotaxis focuses on surgical robotics for minimally invasive endovascular interventions.

What will David Fischel discuss at the conference?

David Fischel will participate in a fireside discussion at the conference.

Last updated: Nov 24, 2025